Table 3.
MIHC analysis between TP53I13 expression level and different clinical characteristics based on samples from Nantong University Affiliated Hospital.
| Characteristic | Levels | TP53I13 | Total | X2 | P | |
|---|---|---|---|---|---|---|
| Low expression of TP53I13 | High expression of TP53I13 | |||||
| n | 74 | 109 | ||||
| Age | ≤60 | 51 (40.8%) | 74 (59.2%) | 125 | 0.022 | 0.883 |
| >60 | 23 (39.7%) | 35 (60.3%) | 58 | |||
| Gender | Female | 33 (40.7%) | 48 (59.3%) | 81 | 0.006 | 0.941 |
| Male | 41 (40.2%) | 61 (59.8%) | 102 | |||
| IDH status | Wildtype | 8 (26.7%) | 22 (73.3%) | 30 | 2.825 | 0.093 |
| Mutant | 66 (43.1%) | 87 (56.9%) | 153 | |||
| Type | AA, AG, and AGG | 6 (54.5%) | 5 (45.5%) | 11 | 3.41 | 0.492 |
| AOA, A, DA, and OG | 39 (40.2%) | 58 (59.8%) | 97 | |||
| GBM | 14 (33.3%) | 28 (66.7%) | 42 | |||
| MG | 10 (40.0%) | 15 (60.0%) | 25 | |||
| PA, PPXA, and PMA | 5 (62.5%) | 3 (37.5%) | 8 | |||
| WHO grade | G3 | 24 (51.1%) | 23 (48.9%) | 47 | 6.77 | 0.034 |
| G4 | 29 (31.2%) | 64 (68.8%) | 93 | |||
| G5 | 21 (48.8%) | 22 (51.2%) | 43 | |||